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management practices, high altitude is associated with 
higher hemoglobin and lower mortality, despite lower uti-
lization of ESA and IV iron.
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Introduction
Anemia is a common feature of chronic kidney disease 
(CKD). It is caused by diminished erythropoietin produc-
tion within the failing kidney, compounded by other fac-
tors, including nutritional deficiencies, inflammation, and 
blood loss ([1, 2 ] and references therein). Because anemia 
is associated with increased morbidity and transfusion risk 
in patients on dialysis, treatments such as IV iron and eryth-
ropoiesis-stimulating agents (ESA) have been fundamental 
aspects of CKD management for the past two decades [1, 
3 ]. However, treatment with high doses of ESA has been 
associated with poor survival [4–8].
Erythropoiesis and iron metabolism are responsive 
to oxygen partial pressure ([9] nd ferences therein). 
Because oxygen partial pressure varies by altitude, com-
parison of outcomes among CKD patients residing at or 
near sea level versus higher altitudes may contribute to an 
understanding of the factors underlying the risk of adverse 
outcomes associated with high-dose ESA use. Prior studies 
at evaluated associations between altitude and outcomes 
among CKD patients found that those residing at higher 
altitudes achieved similar or higher hemoglobin (Hb) levels 
while utilizing less ESA [10, 11], and had reduced mortality 
[12–14], as compared to those residing closer to sea level. 
These data support the premise that the deleterious effects 
of ES  on survival are independent of achieved Hb levels, 
Abstract Residence at higher altitude has been associ-
ated with improved anemia parameters and lower mortal-
ity rates among end-stage renal disease (ESRD) pat ents. 
However, these associations were observed prior to the 
2011 shift in erythropoiesis-stimulating agent (ESA) os-
ing. To determine the impact of altitude on contemporary 
ESRD patients, a retrospective observational analysis was 
conducted in which patients were ascribed to one of four 
altitude categories as of 1 Ja  2012 and outcomes were 
assessed during 2012. Associations between altitude cate-
gory and outcomes were estimat d us ng generalized linear 
mixed models, adjusted for covariate  that differed at base-
line. Patients at higher altitude were less likely to rec ive 
ESA treatment, and dose was 723 U/treatment (95 % confi-
dence interval [CI]: 544, 834) lower in the highest altitude 
category compared to the lowe t category. The proportion 
of patients using IV iron decreased with increa ng alti-
tude category. Patients in the highest two categories had 
greater mean hemoglobin values (+0.15 and +0.23 g/dL) 
than the lowest. Mortality was lower for patients in the 
highest altitude category compared to those in the lowest 
(incidence rate ratio 0.73; 95 % CI: 0.63, 0.88), although 
their rate of missed dialysis treatments was slightly higher. 
This study confirms that, in the context of current anemia 
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altitude (1500-foot increments) were used for associative 
analyses.
Outcomes
ESA utilization was calculated as the mean per treatment 
dose (expressed as U/treatment) during the month among all 
patients, including both ESA users and non-users. ESA use 
was assessed as the proportion of patients using ESA dur-
ing the corresponding month. ESA dose among users was 
calculated as the mean per-treatment dose (expressed as U/
treatment) during the month among patients who used ESA. 
IV iron utilization, use and dose were assessed similarly to 
ESA except that values were expressed as monthly cumula-
tive values (as opposed to per-treatment values) to accom-
modate weekly dosing frequency. Hb level was considered 
as the initial value recorded for each patient during each 
month of follow-up.
The above data were used to calculate metrics of ESA 
response. ESA hyporesponsiveness was defined as two 
consecutive bimonthly hemoglobin measures <10 g/dL in 
the setting of a concurrent averaged ESA dose >7700 U/
treatment in every month. ESA Response Index (ERI) was 
defined as the mean monthly ESA dose divided by the mean 
monthly hemoglobin measure in every month.
Mortality was identified through death records and the 
mortality rate was calculated as number of events divided by 
the time at risk. Missed dialysis treatment rate was defined 
as the number of missed dialysis sessions (not rescheduled, 
identified from LDO records) divided by time at risk.
Statistical analysis
Baseline patient characteristics were described as means, 
standard deviations, medians, interquartile ranges, counts, 
and proportions as dictated by data type. These were com-
pared across altitude categories by ANOVA, Kruskal Wallis 
tests, and chi squared tests as appropriate.
Continuous outcomes, including ESA utilization and IV 
iron utilization, were described as means, standard deviations, 
medians, and interquartile ranges. Differences in use and dose 
among users of ESA and IV iron were compared using gener-
alized linear mixed models (GLMM) with fixed effects terms 
for month of follow up and altitude category and with random 
patient intercepts. Resultant comparisons across altitude cat-
egories are expressed as mean differences (95 % confidence 
interval [CI]). Event outcomes were summarized as counts 
and proportions. Prevalence across altitude categories was 
compared using GLMM as above, and expressed as mean 
differences in prevalence (95 % CI). Rate outcomes were fit 
assuming a GLMM-type model. The outcome was specified 
as a negative binomial. Confidence intervals were determined 
although the relative contribution of Hb excurs ons remains 
unclear.
Importantly, all prior investigations of the impact of alti-
tude on anemia in CKD patients ilized patient data col-
lected prior to 2011. As a result of changes to the ESA labels 
and reimbursement policy in the Un ted State  [15–17], 
there has been a dramatic decline in the m an ESA dose 
among users [18, 19] and the percentage of patients receiv-
ing very high ESA doses [20] since that time. In is study, 
we sought to determine whether the associations between 
altitude, ESA use, and outcomes observed prior to the policy 
changes of 2011 could be confirmed within the context of 
contemporary ESA prescribing practices. In partic lar, we 
examined anemia management param ters, rates of missed 
hemodialysis sessions (a surrogate for hospitalizations), and 
mortality.
Methods
Data source and study population
We conducted a retrospective, observational analysis of 
patients receiving in-center h modialysis at a large dialysis 
organization (LDO) in the United States during the p riod 
01 January—31 December 2012. Patients included in t  
analysis were those who, as of 01 J nuary 2012, were at 
least 18 years old, were not US Veterans Affairs beneficia-
ries (contractual stipulation), and had a dialy is v ntage of 
at least 6 months (to allow for quilibration of anemia man-
agement after dialysis initiation). Patients were followed 
forward from 01 January 2012 for 12 months or until cen-
soring due to transfer of care away from the LDO, change 
in dialysis modality, transplant, r covery of ren l function, 
withdrawal from dialysis, or death. All data were d r ved 
from the electronic health records (EHR) of the LDO, which 
contains information on patient emographics, dise s  his-
tory, comorbidities, dialysis-specific information for each 
treatment session, laboratory results such as hemoglobin, 
and IV anemia medications adminis ered at dialysis ses-
sions (ESAs and iron). The LDO uses a si gle ESA (epoetin 
alfa), which is delivered intravenously.
This observational study w s conduct d retrosp c ively 
using de-identified patient data; the protocol was reviewed 
by an institutional review bo rd (Quorum, Seat le, WA) and 
determined to be exempt. We adh r d to th  Declaration of 
Helsinki and informed consent was not required.
Exposure
The exposure of interest was ltitude, which was determined 
by clinic zip code as of 01 January 2012. Four categori s of 
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were: age, race, etiology, weight, vintage, vascular access 
type, history of diabetes, congestive heart failure, cerebro-
vascular disease, alcohol abuse, peripheral vascular disease, 
and Charlson comorbidity index.
All analyses were performed using SAS, version 9.2 
(SAS Institute, Inc).
by generating bootstrap estimates with 100 replicates, us ng 
unrestricted sampling (IV iron use and ESA use) or robust 
variance estimators (all other ana yses).
All models were adjusted by the addition of covariate 
terms for patient characteristics that differed significantly 
across altitude categories at baselin  (P < 0.10), which 
Table 1 Baseline patient characteristics by altitude
Altitude category (feet)




≥4500 (n = 2027) P-value
Age, years, mean ± SD 61.6 ± 14.9 61.9 ± 14.6 62.3 ± 14.0 63.0 ± 14.8 <0.001
Sex, n (%) 0.41
Male 50,441 (54.5 %) 1657 (53.1 %) 918 (55.3 %) 1099 (54.2 %)
Female 42,047 (45.5 %) 1461 (46.9 %) 741 (44.7 %) 928 (45.8 %)
Race, n (%) <0.001
White 31,185 (33.7 %) 1540 (49.4 %) 359 (21.6 %) 821 (40.5 %)
Black 38,433 (41.6 %) 446 (14.3 %) 69 (4.2 %) 245 (12.1 %)
Hispanic 16,007 (17.3 %) 609 (19.5 %) 1146 (69.1 %) 390 (19.2 %)
Asian 3491 (3.8 %) 137 (4.4 %) 16 (1.0 %) 45 (2.2 %)
Other/unknown 3374 (3.7 %) 386 (12.4 %) 69 (4.2 %) 526 (26.0 %)
Etiology ESRD, n (%) <0.001
Diabetes 41,288 (44.5 %) 1576 (50.6 %) 992 (59.8 %) 1096 (54.1 %)
Hypertension 29,462 (31.9 %) 785 (25.2 %) 349 (21.0 %) 308 (15.1 %)
Other/unknown 21,740 (23.5 %) 757 (24.3 %) 318 (19.2 %) 623 (30.7 %)
Postdialysis weight, kg, mean ± SD 80.4 ± 22.7 80.8 ± 22.7 77.5 ± 20.1 77.9 ± 21.4 <0.001
Vintage, months <0.001
Median [p25, p75] 38 [20, 68] 36 [19, 63] 46 [22, 74] 43 [23, 76]
Vascular access, n (%) <0.001
Fistula 59,611 (64.5 %) 2118 (67.9 %) 1266 (76.3 %) 1541 (76.0 %)
Graft 21,036 (22.7 %) 599 (19.2 %) 250 (15.1 %) 324 (16.0 %)
Catheter 11,810 (12.8 %) 398 (12.8 %) 142 (8.6 %) 160 (7.9 %)
Diabetes, n (%) 63,611 (68.8 %) 2173 (69.7 %) 1346 (81.1 %) 1495 (73.8 %) <0.001
Congestive heart failure, n (%)11,851 (12.8 %) 355 (11.4 %) 101 (6.1 %) 159 (7.8 %) <0.001
Coronary artery disease, n (%)7271 (7.9 %) 256 (8.2 %) 180 (10.9 %) 140 (6.9 %) <0.001
Cerebrovascular disease, n (%)717 (0.8 33 (1.0 %) 6 (0.4 %) 10 (0.5 %) 0.03
Cancer, n (%) 1878 (2.0 %) 78 (2.5 %) 23 (1.4 %) 51 (2.5 %) 0.03
Infection, n (%) 652 (0.7 %) 23 (0.74 %) 6 (0.4 %) 10 (0.5 %) 0.25
Peripheral vascular disease, n (%)2405 (2.0 %) 125 (4.01 %) 45 (2.7 %) 41 (2.0 %) <0.001
Charlson comorbidity index, mean ± SD 5.49 ± 1.93 5.57 ± 1.93 5.74 ± 1.75 5.68 ± 1.84 <0.001
Ferritin, ng/mL <0.001
Mediana [p25, p75] 790 [549, 1032] 841 [592, 1094]831 [610, 1088]694 [417, 943]
TSAT, mean ± SD a 31.7 ± 14.3 32.5 ± 14.6 33.4 ± 14.8 31.9 ± 14.2 <0.001
PTH, pg/mLa <0.001
Median [p25, p75] 360 [225, 563] 335 [210, 519] 315 [199, 463] 316 [201, 493]
Kt/V, mean ± SD a 1.61 ±0.32 1.68 ±0.33 1.71 ±0.32 1.75 ± 0.35 <0.001
Albumin, g/dL, mean ± SD a 3.96 ± 0.41 3.95 ± 0.41 3.98 ± 0.40 3.94 ± 0.38 <0.001
ESA erythropoiesis-stimulating agent, ESRD end-stage renal disease, TSAT tran ferrin saturation, PTHp rathyr id hormone, SD standard 
deviation














Mean ± SD 3517 ± 3994 3063 ± 3701 2456 ± 3099 2257 ± 3191







Users (%) 88.3 % 85.0 % 82.0 % 74.2 %








Mean ± SD 3983 ± 4027 3606 ± 3764 2995 ± 3177 3043 ± 3367









Mean ± SD 53.9 ± 58.0 48.3 ± 52.3 41.5 ± 45.6 43.1 ± 49.9
Median [p25, p75] 33.2 [17.6, 67.7]29.8 [15.6, 60.7]25  [15.3, 49.3]25.8 [13.8, 
52.9]
U/week
Mean ± SD 11,670 ± 11,639 10,537 ± 10,857 8919 ± 9931 8990 ± 9920









Mean ± SD 46,680 ± 46,556 42,146 ± 43,428 35,675 ± 37,323 35,962 ± 39,681






22 000 [13,200, 
44,000]
U/kg/week
Mean ± SD 157.5 ± 166.3 141.0 ± 150.2 123.4 ± 133.0 127.4 ± 147.2


























Mean ± SD 162 ± 159 162 ± 150 138 ± 152 135 ± 159
Median [p25, p75] 200 [0, 200]200 [0, 200]150 [0, 200]100 [0, 200]
Users (%) 73.2 % 74.6 % 65.6 % 62.8 %






Dose among users, mg/month
Unadjusted modeled mean (95 % CI)b 222 (221, 222) 218 (215, 221) 211 (207, 215) 214 (210, 219)







Mean ± SD 10.89 ± 1.15 10.91 ± 1.17 11.12 ± 1.19 11.14 ± 1.29
Table 2 D scription of anemia outcomes by altitude category
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Patients in the highest two altitude categories were less 
likely to receive IV iron, while achieving higher mean Hb, 
compared to the lowest category. Accounting for differences 
in patient characteristics, altitude ≥4500 ft (vs 0–1499 f ) 
was independently associated with 10.1 % (95 % CI: 8.9, 
11.4 %) fewer patients treated with IV iron (Fig. 1c). Among 
IV iron users, there was no meaningful difference in mean 
monthly iron dose across altitude categories, though point 
estimates were lower for higher altitude categories versus 
0–1499 ft (Fig. 1d).
There was an incremental and monotonic association 
between higher altitude category and lower prevalence 
of ESA hyporesponse. Patients at ≥4500 ft were half as 
likely to be ESA-hyporesponsive as compared to patients 
at 0–1499 ft (3.5 % vs  7.6 %, respectively, Fig. 2a). Cor-
respondingly, mean and median erythropoietin resistance 
index (ERI) was incrementally lower with increasing alti-
tude (Fig. 2b).
Mortality and missed dialysis treatment outcomes by 
altitude category are shown in Table 3. Among patients at 
altitude 0–1499, 1500–2999, 3000–4499 ft and ≥4500 ft, 
crude death rates were 10, 11, 9, and 8 deaths per 100 
patient-years, respectively. Accounting for differences in 
patient characteristics, altitude ≥4500 ft (vs 0–1499 ft) was
independently associated with a 26 % lower risk of death 
(adjusted IRR = 0.74; 95 % CI 0.63, 0.88; Fig. 3a). Adjusted 
death risk was not different for intermediate altitude catego-
ries versus 0–1499 ft.
Altitude ≥4500 ft (vs 0–1499 ft) was also independently 
associated with a 7 % higher rate of missed dialysis treat-
ments (adjusted IRR = 1.07; 95 % C  1.02, 1.12; Fig. 3b), 
after accounting for differences in patient characteristics. 
No statistical differences were detected in missed treatment 
rates between the other altitude groups.
Results
Patients were assigned to one of four al itude ca egories, 
defined and expressed in terms of feet above sea level, 
based on the zip code of their cl ic: 0–1499 (n = 92,490), 
1500–2999 (n = 3118), 3000–4499 (n = 1659), and ≥ 4500 
(n = 2027); categories correspond to 0–456.9, 457–914.1, 
914.2–1371.3 and ≥1371.4 meters above sea evel, resp c-
tively. Baseline characteristics of patients in the four altitude 
categories are shown in Table . Compared to patients in 
the lowest altitude category, patient i  the highest altitude 
category were older with lower dry weight, longer dialysis 
vintage, and higher Kt/V; were more frequ ntly diabetic and 
less likely to have a history of hypertension or congestive 
heart failure; and had lower ferritin values.
Anemia outcomes by altitude category are shown in 
Table 2. Compared to patients at 0–1499 ft, those in higher 
altitude categories (1500–2999, 3000–4499, ≥4500 ft) 
were less likely to receive ESA t e tment. Accounting for 
differences in patient char c eristi s, altitud≥4500 ft (vs 
0–1499 ft) was independently associated with 13.9 % (95 % 
CI: 12.3, 15.5 %) fewer patients treated with ESA (Fig. 1a). 
Among ESA users, there was an incremental nd monotonic 
association between higher altitude ategory and lower ESA 
dose. As compared to the lowest altitude category, altitude
≥4500 ft was independently associated with 723 (95 % 
CI: 544, 834) U/treatment lower ESA ose (Fig. 1b). Alti-
tude≥4500 ft (vs 0–1499 ft) was also ind pendently associ-
ated with 0.23 (95 % CI: 0.19, 0.27) g/dL higher mean Hb 
(Fig. 1e). A similar association was observed w en ESA 
dose was considered per kilogram of body w ight (Supple-
mental Fig. 1), suggesting that this finding is unlikely to be 
due to the fact that patients in the highest altitude cat gory 


























Unadjusted mean difference (95 % CI)b 0 (ref) 0.02 (0.007, 
0.06)
0.23 (0.18, 0.27)26 (0.21, 
0.30)
All analyses were adjusted for age, race, etiology, weight, vintage, access, history of diabetes, congestive heart failure, cerebrovascular disease, 
alcohol abuse, peripheral vascular disease, and Charlson comorbidity index
CI confidence interval, ESA erythropoiesis-stimulating agent, SD standard deviation
aDose among all patients, including non-users
bCI were generated using a bootstrapping method. Adjustments were made for covariates that were imbalanced (P ≥ 0.1) across groups at base-
line
Table 2 (continued) 
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limited dosing options available to prescribing physicians. 
Although net utilization of anemia medications among 
patients living at higher altitudes was lower, these patients’ 
mean Hb was higher. Together, these trends contributed to 
the lower ERI scores observed at higher altitudes. Impor-
tantly, a lower incidence of ESA hyporesponse was also 
observed at higher altitude. This finding is clinically signifi-
cant, because patients with ESA hyporesponse have worse 
outcomes than patients with a normal response to ESA.
Discussion
This analysis revealed that, among contemporary ESRD 
patients following revised ESA dosing paradigms, resid nce 
at high altitude (≥4500 f ) was associated with improved 
anemia outcomes compared to residence closer to s a l vel 
(0–1499 ft). These improvements included a lower propor-
tion of users of both ESA and iro . Iron do  among users 



























































































































































Fig. 1 Anemia management parameters by altitude category. a The 
adjusted difference in percent users of ESA [95 % confidence interval 
(CI)] is presented. b The adjusted mean difference (95 % CI) in ESA 
dose among users (U/treatment) is presented. c The adjusted differ-
ence in percent users of IV iron (95 % CI) i  presented. d The a justed 
mean difference (95 % CI) in IV iron dose among users (mg/month) 
is present d. e The adjusted mean difference (95 % CI) in hemoglobin 
concentration (mg/dL) is presented. Across all panels, the 0–1499 ft 
category serves as the referent (ref). All analyses were adjusted for 
age, rac , etiology, weight, vintage, access, history of diabetes, con-
gestive heart failure, cerebrovascular disease, alcohol abuse, periph-





















0-1499 1500-2999 3000-4499  ≥ 4500
Altitude Category (ft)
0-1499 1500-2999 3000-4499  ≥ 4500
ba ESA Hyporesponse Erythropoietin Resistance Index
Fig. 2 Erythropoiesis stimulating agent responsiveness metrics by 
altitude category. a The proportion of patients within each altitude 
category displaying ESA hyporesponse, defined as two consecutive 
bimonthly hemoglobin measures <10 g/dL in the setting of a concur-
rent averaged ESA dose >7700 U/treatment, is presented. b Mean 
(squar  symbols) and dian (round symbols) erythropoietin resis-
ta ce index (ERI) scores for patients in each altitude category are pre-
sented. ERI is calculated as the mean monthly ESA dose divided by the 




decreased EPO resistance as compared to patients residing 
at lower elevations [11]. Sim lar effects were also observed 
when patients residing at low altitude moved to a higher 
altitude [10]. Although the direction of change is similar 
to that observed in our study, direct comparison of differ-
ences in ESA dose among altitude groups across studies is 
The improved anemia outcomes observed in our study 
are consistent with previous studies conducted using pati nt 
data obtained prior to the changes in ESA dosing practices 
triggered by policy reform in 2011. A previous analysis 
found that patients residing a  al itudes above 6000 ft had 
reduced erythropoietin (EPO) use, increased hematocri , an  
Table 3 D scription of mortality and missed dialysis treatments by altitude category
Altitude category (feet)
0–1499 1500–2999 3000–4499 ≥4500
Number of patients 92,490 3118 1659 2027
At-risk time, patient-years80,873 2653 1481 1821
Mortality
Number of deaths 7837 292 134 140
Crude ratea 10 11 9 8
Unadjusted modeled rate (95 % CI)a,c 9.6 (9.5, 9.9) 11 (9.8, 12.3) 9 (7.6, 10.7) 8 (6.5, 9.1)
Unadjusted IRR (95 % CI)c 1 (ref) 1.14 (1.01, 1.28)0.93 (0.79, 1.11)0.79 (0.67, 0.94)
Adjusted IRR (95 % CI)c 1 (ref) 1.07 (0.95, 1.21) 1.05 (0.88, 1.24)0.74 (0.63, 0.88)
Missed dialysis treatments
Number of missed treatments976,200 31,707 15,321 21,924
Crude rateb 12.07 11.95 10.35 12.04
Unadjusted modeled rate (95 % CI)b,c 12.07 (11.98, 12.15)11.94 (11.45, 12.45)10.33 (9.78, 10.91)12.05 (11.45, 
12.69)
Unadjusted IRR (95 % CI)c 1 (ref) 0.99 (0.95, 1.03) 0.86 (0.81, 0.90)1.00 (0.95, 1.05)
Adjusted IRR (95 % CI)c 1 (ref) 1.04 (1.00, 1.08)0.97 (0.92, 1.02)1.07 (1.02, 1.12)
All analyses were adjusted for age, race, etiology, weight, vintage, access, diabetes, congestive heart failure, cerebrovascular disease, alcohol 
abuse, peripheral vascular disease, and Charlson comorbidity index
CI confidence interval, IRR incidence rate ratio
aDeaths per 100 patient-years
bMissed treatments per patient-year
cCI were generated using a bootstrapping method. Adjustments were made for covariates that were imbalanced (P ≥ 0.1) across groups at base-
line
215.0
Adjusted IRR (95% CI)
a Mortality





































Adjusted IRR (95% CI)
b Missed Dialysis Treatments
Favors higher altitude Favors higher altitude tf9941-0 edutitla srovaFtf9941-0 edutitla srovaF
Fig. 3 Mortality and missed dialysis treatments by altitude category. 
a The adjusted incidence rate ratio (IRR, 95 % CI) fo  mort l ty is pre-
sented for each altitude category with respect to the referent (ref) cat-
egory of 0–1499 ft. b The IRR (95 % CI) for missed dialysis treatments 
is presented for each altitude category with respect to the referent 
category of 0–1499 ft. All analyses were adjusted for age, race, eti-
ology, weight, vintage, access, history of diabetes, congestive heart 
fa lu , c rebrovascula  disease, lcohol abuse, peripheral vascular 




treatment rate. Missed dialysis treatments are often due to 
hospitalizations (limitations in the source data precluded 
the ability to look at hospitalizations directly), and thus 
the increased missed treatment rate might suggest a higher 
hospitalization rate among patients living at higher altitude. 
However, longer travel distances and more frequent inclem-
ent weather at higher altitude clinics may also contribute to 
the higher missed treatment rate. Further studies, designed 
specifically to address this issue, are needed to clarify asso-
ciations between hospitalization rates and altitude.
This study has the following limitations. First, our study 
was observational; associations can be measured but cause 
and effect are not determined. Second, despite adjustment 
for covariates that differed at baseline, it is possible that 
unknown confounding may influence study results. Third, 
altitude assignments were based upon clinic zip code, not 
residential address. Fourth, there was limited precision in 
point estimates at the highest altitude. Fifth, C-reactive pro-
tein values were not available, and thus inflammation status 
could not be determined within the study cohort.
Conclusions
Our findings confirm that the positive association between 
higher altitude and patient outcomes is still evident in the 
context of current anemia management. Our study thus 
provides additional evidence to support the suggestion that 
this association is the result of underlying biological mecha-
nisms, as opposed to an artifact of previous care standards. 
Treatments that mimic the effect of higher altitude may 
therefore be beneficial for patients with renal anemia.
Acknowledgments Th  authors thank DaVita Clinical Research 
(DCR) for providing technical support for this research project, and 
Dena E. Cohen, Ph.D., for medical writing support. The present manu-
script and the corresponding analyses were supported by Akebia Ther-
apeutics, Inc.
Compliance with ethical standards
Conflict of Interest BJM is employed by Akebia, Inc and owns 
stock therein. SMB and SS are employed by DCR. SMB’s spouse is 
employed by AstraZeneca.
Ethical approval All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards.  For this type of study formal consent is not required.  This 
article does not contain any studies with animals performed by the 
authors
Open Access Thi  article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://cre-
ativecommons.org/licenses/by/4.0/), wh h p rmits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
precluded by the recent changes to the US ESA labels and 
subsequent changes in prescribing practice.
Previous studies did not address the use f IV iron with 
respect to altitude. Our novel observation that the propor-
tion of patients using IV iron is lower  higher altitudes 
suggests that clinically significant differences in iron utili-
zation may exist between patients  low versus high alti-
tude. Moreover, these results ind cate that the high r Hb 
achieved among patients resid ng at higher lti ude, despite 
lower ESA use, was not due to more aggressiv  treatment 
with IV iron.
Together, these findings are consistent with the idea that 
activation of the hypoxia inducibl  factor (HIF) family of 
transcription factors by the lower partial pressure of oxy-
gen found at higher elevations leads to favorable changes in 
dialysis patients [21]. Potentially beneficial effects of HIF 
activation include mobilization of iron from storage pools, 
increasing synthesis of endogenou  ery hropoietin, and 
increasing the erythropoietic r sponse to both endogenous 
and exogenous erythropoietin. These beneficial effects may 
contribute to the lower need for anemia medications among 
patients in our study residing at high altitude. Consistent 
with previous literature [12, 13], w  obse ved a lower mor-
tality rate among patients residing at ≥4500 ft compared to 
<1500 ft. This effect was observe  even t ough our study 
defined altitude based on clinic zip code rather than resi-
dential zip code, used differe  categories of altitude, and 
was conducted after a marked shift in anem a treatment 
practices as compared to previous work. Furthermore, the 
present study was conducted when mortality rates were gen-
erally lower than observed du ing prior studies, mostly du  
to improvements in infection c ntrol [3]. I  spite of these 
differences, the magnitude of the effect observed here is 
probably comparable to that which was r ported previously.
Studies of ESA use in chronic kidney disease have shown 
that higher ESA doses are associated with greater mortality 
[22, 23]. From these prior studies, it wa  not clear whether 
the higher mortality rate was caused by the increase in Hb 
levels, or whether the higher mort lity rate was a result of 
confounding (sicker patients receive more ESA, and sicker 
patients are also more likely to di ). The results of the study 
presented here provide context in which to interpret these 
prior studies. Here, we observe a group of patients (namely 
those residing at high altitude) who, compared to cont ols 
(those residing at or near sea level), have similar baseline 
characteristics and prognostic features, and who, despite 
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